Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited announced the issuance of 210,000 unquoted equity securities under an employee share scheme. This move is part of the company’s strategy to incentivize and retain talent, potentially strengthening its operational capabilities and aligning employee interests with company growth.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.
Average Trading Volume: 617,468
Technical Sentiment Signal: Buy
Current Market Cap: A$1.77B
See more data about NEU stock on TipRanks’ Stock Analysis page.